KR20150008238A - Anti-UV Composition for Skin External Application Comprising Peptide derivatives from Extract of Microalgae Comprising the Same - Google Patents

Abstract

The present invention relates to a skin external application composition containing a peptide derivative obtained from a microalgae extract for blocking UV rays. More specifically, the present invention relates to: the peptide derivative in which mycosporine-like amino acid and a neuropeptide derived from the microalgae extract are bound to each other. The mycosporine-like amino acid is selected from a group consisting of Porphyra 334, Shinorine, Palythine, and Asterine. The neuropeptide is selected from a group consisting of neoendorphin, exorphin, and encephalin. According to the present invention, the skin external application composition has an excellent UV blocking effect, is less irritating to skin, and has an excellent effect of blocking UV rays in everyday life.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention [0001] The present invention relates to a composition for external application for skin protecting against UV rays containing a peptide derivative derived from a microalgae extract,

The present invention relates to a composition for external application for skin for protecting ultraviolet rays containing a peptide derivative derived from a microalgae extract, and more particularly, to a composition for external application for skin for protecting ultraviolet rays comprising peptide derivative derived from microalgae extract and a peptide derivative to which neuroprecipitate is bound, To a skin external application composition for screening.

The ultraviolet rays emitted from the sun are composed of a long wavelength (region of about 320-400 nm) called UV A (ultraviolet A) and a short wavelength (about 290-320 nm) called UV B (ultraviolet ray B). In the sunlight, about 6% of ultraviolet rays A and B reach the surface of the earth. Ultraviolet rays C are absorbed and scattered in the ozone layer and the atmosphere, and they do not reach the ground surface.

These ultraviolet rays have advantages such as the synthesis of vitamin D in the body, the treatment of skin diseases, the sterilization effect, but there are harmful aspects such as sunburn, skin cancer, skin aging, photosensitivity skin disease and mutagenesis. Ultraviolet A penetrates into the dermis and mainly causes pigmentation and aging of the skin, and is involved in the development of photosensitivity dermatitis. Ultraviolet B penetrates into the epidermis and upper part of the dermis with a shorter wavelength of high energy rays and causes sunburn, pigmentation and skin cancer It is known to be involved.

There has been an attempt to shield sunlight from ancient times to prevent these side effects of sunlight. There are chemical sunscreen agents and physical sunscreen agents. Chemical sunscreens mainly absorb sunlight, while physical sunscreens prevent sunlight from penetrating through reflection and scattering.

The performance of a physical or chemical UV protection product is usually expressed in Sun Protection Factor (SPF). Specifically, the ultraviolet barrier index is an index indicating the blocking effect against UVB. The minimum erythemal dose (MED) obtained by irradiating UVB to a region not coated with the ultraviolet screening product is defined as a minimum It is the relative value divided by erythema amount. The minimum erythema amount refers to the minimum amount of ultraviolet light that causes erythema to appear in almost all of the irradiated area after 1624 hours of irradiation of human skin with UVB.

On the other hand, the minimum ultraviolet irradiation dose at which faint blackening is basically recognized in the entire region of the irradiation area after UV A irradiation is referred to as a minimum persistent pigment darkening dose (MPPD). At this time, the MPPD ratio of the product application site and the non-application site is called the Protection Factor of UVA (PFA). The ultraviolet A blocking level (PA) is an index indicating the degree of UV A blocking effect.

In ancient times, there were physical methods of avoiding or covering the sun, and attempts to mix tar, herb and mud to the skin. When the sunlight is irradiated on the skin, the amount of melanin in the skin epidermal layer is increased. This melanin is a substance in vivo and has a capability of absorbing ultraviolet rays, and has a function of removing free radicals generated by ultraviolet rays in the process of being produced. Thus, melanin has been a very important and excellent UV sunscreen that prevents skin damage.

The chemical sunscreens contain at least one component that absorbs ultraviolet rays. These include sunscreens such as PABA, PABA esters (Amyl dimethyl PABA, octyl dimethyl PABA), Cinnamates (Cinoxate), Salicylate (Homomenthyl salicylate) , Benzophenone (Oxybenzone, Dioxybenzone, Suliso benzene), Dibenzoyl methane, and Anthranilate which mainly block ultraviolet ray A are known. These chemical sunscreens have the effect of absorbing ultraviolet light, but some of them are irritating to the skin or eyes (PABA, PABA esters, benzophenones, cinnamates, etc. have been reported to cause contact dermatitis) , And thus limit the use thereof or limit the use thereof.

A physical sunscreen is a natural component that protects the skin by reflecting and scattering ultraviolet light penetrating the skin. Titanium dioxide, Talc, Magnesium oxide, Zinc oxide, and Kaolin are examples of such materials. The physical ultraviolet screening agent can realize ultraviolet ray blocking effect of both ultraviolet rays A and B. There is no side effect such as contact dermatitis and it is not easily washed out with water. However, it is difficult to maintain effective content while realizing a desired formulation, There is a disadvantage that clouding phenomenon occurs.

Conventional organic or inorganic UV blocking materials have various problems such as lower stability or skin troubles when they are contained in cosmetic formulations over a certain amount, and safety, efficacy and stability of sunscreen agents are important topics of cosmetics. In the case of UV protection cosmetics that protect skin from ultraviolet rays due to the nature of cosmetics, materials that can act as UV blocking agents are natural-friendly, environmentally friendly, have a high skin fit, and are also capable of stimulating consumers' Development is necessary. In the case of ultraviolet shielding materials, recently, it is active in the nature-friendly and environment-friendly plant material. Especially, the ingredients extracted from plant material in Europe are consumed through authentication such as Eco-CERT. Natural Cosmetics or Organic Cosmetics Hida's efforts to go are outstanding.

As a part of the defense mechanism against ultraviolet irradiation in the terrestrial plants, there is a case where the synthesis of aromatic compounds such as phenylalanine, tyrosine, tryptophan and purine and pyrimidine is induced in the flavonoid pigments such as gallic acid and caffeic acid and the like. There have been no studies on the UV defense mechanism of marine plants directly influenced by UV irradiation. Recently, studies on UV protection have been actively conducted mainly on mycosporine-like amino acids (MAAs). MAAs derived from microalgae are Asterina, Shinorine, and Porphyra, which are known to be effective for the treatment of neurological diseases (Korean Patent Application No. 10-2008-7031246)

Accordingly, the development of a natural material for sunscreen without serious side effects such as skin irritation, allergic reaction and toxicity such as irritant dermatitis, contact dermatitis, photoallergic dermatitis and the like without giving a heavy feeling or residue to the skin, Is required.

Korean Patent Application No. 1020087031246 An agent for treating nervous system diseases, neurodegenerative diseases and mood disorders, an extract thereof, and a purified component thereof

The inventors of the present invention have found that microalgae ( Chlamydomonas sp . And Chlamydomonas sp .) , Which have ultraviolet ray absorbing ability but have difficulty in artificial cultivation and separation purification conditions, using hedleyi), from which Mycosporine-like amino acid (MAA) the separation and purification of the Neuropeptide having a skin cell activity Enkephalin, Neoendorphin, and plant-derived peptides of Exorphin the MAA-Neuropeptides Solid-Phase Peptide Synthesis (SPPS using ) Method, and their UV blocking ability was newly confirmed, thereby completing the present invention.

Accordingly, an object of the present invention is to provide a peptide derivative in which neuropeptides are bound to mycosporine-like amino acids (MAA).

It is an object of the present invention to provide a composition for external application for skin and a composition for protecting ultraviolet rays, which comprise the peptide derivative.

The present invention provides peptide derivatives in which neuropeptides are bound to mycosporine-like amino acids (MAA).

In one embodiment, the present invention provides a composition comprising mycosporine-like amino acids selected from the group consisting of Porphyra 334, Shinorine, Palythine and Asterine, MAA) with a neuropeptide selected from the group consisting of neodendrine, exopin, and enkephalin.

The present invention provides a composition for external application for skin and a composition for protecting ultraviolet rays comprising the peptide derivative.

INDUSTRIAL APPLICABILITY The composition for external application for skin according to the present invention is excellent in ultraviolet ray shielding effect and has little irritation on the skin, which is excellent in prevention of ultraviolet ray blocking in everyday life.

Figure 1 schematically shows the process of extraction of a mycosporin-like amino acid from a species of Clamidomonas species (methanol solution), removal of a polysaccharide fraction and concentration (roto evaporation and freeze-drying), which are necessary for the production of a peptide derivative according to the present invention Fig.
FIG. 2 is a graph showing the results of HPLC chromatogram analysis of synolin isolated from Clamidomonas sp.
FIG. 3 is a graph showing the HPLC chromatogram results of the extracted fraction mixed with astelin 330, palatin, and synorin, isolated from Clamidomonas sp. FIG. 5 is a graph showing the results of HPLC chromatogram analysis of the target lipase. FIG.
FIG. 4 is a graph showing the results of HPLC chromatogram analysis of a micosporine-glycine (M-Gly) -extracted fraction isolated from Clamidomonas sp.
FIG. 5 is a graph showing the results of HPLC chromatogram analysis of extracted fractions containing porphyran 334, synorin, palatin, and astelin isolated from Clamidomonas sp.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.

Hereinafter, the present invention will be described in detail.

The present inventors have found that, when Chlamydomonas species sp.) separating the extract fractions having ultraviolet absorbing ability purified Asterine-Neoendorphin, using a neuropeptide with the obtained active material for the skin cells to Asterine-Enkephalin, Asterine-Exorphin, Shinorine-Neoendorphin, Shinorine-Enkephalin, Shinorine- from Exorphin, Porphyra-Neoendorphin, Porphyra-Enkephalin, and Porphyra-Exorphin were synthesized, and they were confirmed to have ultraviolet blocking ability and completed the present invention.

In one aspect, the present invention relates to a peptide derivative to which neuropeptide is attached to a mycophorine-like amino acid.

About 20 kinds of mycosporine-like amino acids (MAA) are known, and the types and structure of MAAs are described in J. Phycol. 34, 418430 (1998) disclose the chemical structure of each mycosporin-like amino acid. Particularly, the structures of porphyran 334, synorin, palatin and asustin, which are MAAs presented as one embodiment in the present invention, are as follows.

[Fig.1] porphyra 334

[Figure 2] shinorine

[Figure 3] asterine

[Figure 4] palythine

These MAAs are derived from microalgae of Chlamydomonas. In the present invention, microomonas microalgae were purchased from the Korea Ocean Research & Development Institute, but also from Korea Biotechnology Research Institute. Such climidomonas microalgae can be cultured through various culture media and culture conditions for culturing microalgae, which are conventionally known, and are not limited to the culture conditions shown in the examples. In particular, it is derived from Chlamydomonas sp. Or Chlamydomonas hedleyi .

The mycosporin-like amino acid according to the present invention can be extracted from the climidomonas microalgae using an organic solvent. Water, an organic solvent, or a mixed solvent thereof. The extracted liquid can be used directly or by concentrating and / or drying. In the case of extraction using an organic solvent, an organic solvent such as methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof. The active ingredient of the herbal medicine may be extracted at room temperature or warmed under the condition that the active ingredient is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient of the medicament may differ. Therefore, an appropriate organic solvent should be selected and used. It can also be obtained through various known extraction methods not specifically mentioned herein, such as physical methods, hot water extraction, ethanol extraction, and the like.

In particular, it can be extracted as an embodiment through the separation process shown in FIG.

The results of separation of mycosporin-like amino acids extracted from Clamidomonas according to Examples 1-2 and Fig. 1 can be confirmed by the HPLC chromatogram analysis graph shown in Figs. 2 to 5. As a result of the analysis on the total of four extracted fractions, the extracted fractions of Figs. 2 to 5 each had synorhin, Fig. 3 shows a mixture of astelin 330 and palatin and synorin, Fig. 4 shows the results of mycophorin- Extract fractions and FIG. 5 relates to a mixed extract fraction of porphyran 334, synorin, palatin, and astelin, which are used as mobile phases in C8 chromatographic columns with 0.1% acetic acid (v / v) 2.5% / v), which is an extract fraction obtained after extraction. Each extracted fraction was identified by HPLC.

In the present invention, neuropeptides are peptides secreted from nerve cells, which are known to act on nerve cells to induce activity and induce activation of skin tissue through various signal transduction processes. Examples of such neuropeptides include neoendorphin, alpha endorphin, gamma endorphin, enkephalin and exopine. In one embodiment of the present invention, neuroendodyne (YGGFLRKYPK: SEQ ID NO: 1), exopine (YGGWL: Enkephalin (YGGFL: SEQ ID NO: 3), and can be synthesized by the method shown in Example 1-3.

Such mycosporin-like amino acids and neuropeptides are prepared as novel peptide derivatives through a series of synthetic procedures, and the specific procedure thereof can be obtained through various processes described in Examples 1-3.

Specifically, the exemplary structures of the novel peptide derivatives synthesized through Examples 1-3 are as follows:

[Figure 5] Porphyra 334-neoendolpin peptide derivative

[Figure 6] Porphyra 334-Exopin peptide derivatives

[Figure 7] Porphyra 334-Enkephalin peptide derivatives

In another aspect, the present invention relates to a composition for external application for skin containing the peptide derivative as an active ingredient, and to a composition for external application for skin having ultraviolet blocking effect.

In the present invention, the peptide derivative or the microalgae microalgae extract may contain 0.1 to 10% by weight based on the total weight of the composition. When the content is less than 0.1% by weight, the effect is insignificant. When the content is more than 10% by weight, there are problems of safety and formulation stability.

In the present invention, the expression "comprising as an active ingredient" means that the composition is an external composition for skin and contains such an effective amount to block ultraviolet rays.

In another aspect, the present invention relates to a composition for external application for skin for ultraviolet shielding, wherein the neuropeptide is mixed with a mycosporin-like amino acid. Such a composition for external application for skin comprises at least one kind of neuropeptide and mycosporin-like amino acid. The specific neuropeptide and the kind of mycosone-like amino acid are as mentioned above. As shown in the examples, 334, palatin, astelin, and / or synorin and a neuropeptide (neodendrine, exopine and / or enkephalin).

In the present invention, the composition for external application for skin may be a cosmetic composition or a pharmaceutical composition.

The cosmetic composition of the present invention may contain an acceptable carrier in cosmetic preparations. Herein, "an acceptable carrier for a cosmetic preparation" is a known or used compound or composition that can be contained in a cosmetic preparation, or a compound or composition to be developed in the future, which is toxic, instable or irritating It says nothing.

The carrier may be included in the skin topical composition of the present invention in an amount of from about 1% by weight to about 99.99% by weight, preferably from about 90% by weight to about 99.99% by weight of the composition, based on the total weight thereof. However, since the ratio varies depending on the formulations described below in which the composition for external application for skin of the present invention is prepared, and its specific application site (face, neck, etc.) or its preferable application amount and the like, And should not be construed as limiting the scope of the invention.

Examples of the carrier include an alcohol, an oil, a surfactant, a fatty acid, a silicone oil, a wetting agent, a moisturizer, a viscous modifier, an emulsifier, a stabilizer, an ultraviolet scattering agent, an ultraviolet absorber, a coloring agent and a perfume. The compounds / compositions which can be used as the above-mentioned alcohol, oil, surfactant, fatty acid, silicone oil, humectant, humectant, viscous modifier, emulsifier, stabilizer, ultraviolet scattering agent, ultraviolet absorber, The person skilled in the art can select and use the appropriate substance / composition. In addition, conventionally known organic / inorganic UV blocking agents and natural products known to have ultraviolet shielding function may be additionally included.

As an embodiment of the present invention, the composition for external application for skin according to the present invention may further comprise, in addition to a peptide derivative or clomidomonas extract to which neuropeptide is conjugated to the mycosporin-like amino acid, glycerin, butylene glycol, propylene glycol, polyoxyethylene hydrogenated castor oil Ethanol, triethanolamine and the like, and may contain a minor amount of preservatives, flavors, coloring agents, purified water and the like as needed.

The composition for external application for skin according to the present invention can be prepared in various forms such as lotion, essence, gel, emulsion, lotion, cream (underwater type, water type, multiphase), solution, suspension ), Capsules (soft capsules, hard capsules) having a coating such as anhydrous products (oil and glycol), gel, mask, pack, powder or gelatin.

The method for preparing a skin external composition containing a peptide derivative in which neuropeptides are bound to a mycosporin-like amino acid according to the present invention is not limited to the methods disclosed in the Examples, and any person skilled in the art The external preparation for skin according to the present invention can also be prepared by a method in which the production method is partially modified.

In particular, the composition for external application for skin may be prepared in the form of a general emulsified formulation and a solubilized formulation, by a known manufacturing method, in addition to the manufacturing method specifically disclosed in the present invention.

When the cosmetic composition is manufactured from a cosmetic composition, the cosmetic composition of the emulsified formulation includes nutritional lotion, cream, essence and the like. It can also be prepared in the form of adjuvants which can be applied topically or systemically, which are conventionally used in the field of dermatology by containing a dermatologically acceptable medium or base.

In addition, suitable cosmetic formulations include, for example, solutions, gels, solid or kneaded anhydrous products, emulsions obtained by dispersing an oil phase in water, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) May be provided in the form of a follicular dispersing agent of the type, cream, skin, lotion, powder, ointment, spray or conical stick. It can also be prepared in the form of a foam or an aerosol composition further containing a compressed propellant.

In addition, the composition for external application for skin of the present invention may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softening agents, antioxidants, suspending agents, stabilizers, foaming agents, A lipid vesicle or a cosmetically active agent, a lipid vesicle or a cosmetically active agent, a lipid vesicle or a cosmetically active agent, a stabilizer, a stabilizer, Such as other ingredients of the cosmetic or dermatological science. And, the above ingredients can be introduced in amounts commonly used in the field of dermatology.

The composition for external application for skin according to the present invention includes a form of functional cosmetics capable of preventing aging of skin caused by ultraviolet ray shielding.

Such a pharmaceutical composition may contain, in addition to the peptide derivative or clomidomonas extract as an active ingredient, a "pharmaceutically acceptable carrier ", which may be a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, ≪ / RTI > The pharmaceutical composition may further comprise an additive. The additives may include flavoring agents, vitamins, and antioxidants. Examples of the diluent include lactose, dextrin, tapioca starch, corn starch, soybean oil, microcrystalline cellulose or mannitol as a carrier, magnesium stearate or talc as a lubricant, , And the binding agent may be polyvinylpyrrolidone or hydroxypropylcellulose. Examples of the disintegrant include carboxymethylcellulose calcium, sodium starch glycolate, polacrilin potassium, or crospovidone; examples of sweeteners include white sugar, fructose, sorbitol, or aspartame; stabilizers include sodium carboxymethylcellulose, Or xanthan gum, and the preservative may be methyl paraoxybenzoate, propyl p-hydroxybenzoate, or potassium sorbate.

The pharmaceutical composition may be formulated into conventional pharmaceutical formulations known in the art. The pharmaceutical composition may be formulated and administered in the form of an oral administration preparation, an injection preparation, a suppository, a transdermal preparation, and a dosage form. For example, the formulations may be formulated for oral administration, such as solutions, suspensions, powders, granules, tablets, capsules, pills, or expanses.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

Example  1-1: Microalgae Chlamydomonas sp .Wow Chlamydomonas hedley  culture

The Chlamydomonas sp . and Chlamydomonas hedley Was obtained from Korea Ocean Research & Development Institute (KORDI). F / 2 Medium (Guillard and Ryther 1962, Guillard 1975) was prepared using sterile seawater. The cultures were aseptically cultured in Chlamydomonas sp . and Chlamydomonas hedleyi were subcultured in f / 2 medium at intervals of 2 ~ 3 weeks. Then, using a balloon type bioreactor (Samsung Scientific), the liquid medium of the same composition was uniformly regulated at 25 ° C, air supply amount of 0.1 vvm and light intensity of 30 E / m / s (18 h day, 6 h night) Lt; / RTI >

Example  1-2: Microalgae Chlamydomonas sp .Wow Chlamydomonas hedley  from MAA detach

In order to extract the active ingredient from the microalgae of the present inventionChlamydomonas with sp. Chlamydomonas hedley The cultures were washed three times in sterile distilled water at 10,000 rpm for 20 minutes by centrifugation,Chlamydomonas sp .Wow Chlamydomonas hedley Of pellet are collected.Chlamydomonas sp .Wow Chlamydomonas hedley The organic alcohols of the microalgae were extracted with hexane, chloroform, ethyl acetate, butanol and water. The solvent-extracted fractions were subjected to all the experiments by removing the solvent with a vacuum decompression concentrator, measuring the weight of the solids, and adding ethanol to the solids (FIG. 1).

Example  1-3: Solid - Phase Peptide Synthesis ( SPPS ) MAA Conjugated - Neuropeptides  synthesis

Chlamydomonas sp . (SH), asterine 330 (AS330) + palythine (PNE) + shinorine (SH), micosporine-glycine (M-Gly), porphyra 334 (P-334) + shinorine + palythine + asterine, Enkephalin, Exorphin , And the method of combining neoendorphin was a solid phase peptide synthesis method using Fmoc.

(1) Synthesis of Porphyra334-Neoendorphin (YGGFLRKYPK: SEQ ID NO: 1)

1. Place the Fmoc-Lysine-loaded resin into the vessel, dissolve in NMP (N-Methylpyrrolidinone) and infuse the resin for 20 minutes.

2. A solution of piperidine (20%) and NMP (80%) was added to the inflated resin and the reaction was repeated twice for 10 minutes.

3. Wash 3 times with DCM (Dichloromethane) solution and 3 times with NMP solution.

4. Fmoc-Proline amino acid (10 equivalents of Fmoc-Lysine-loaded resin) was dissolved in NMP and then N-Hydroxysuccinimide (10 equivalents of Fmoc-Lysine-loaded resin), DCC (Dicyclohexylcarbodiimide -loaded resin 10 equivalents).

5. Add 4 solutions to the Lysine-loaded resin with Fmoc removed.

6. Repeat step 25 until the sequence Decapeptide (sequence: YGGFLRKYPK) is synthesized.

7. Porphyra (10 equivalents of Fmoc-Lysine-loaded resin) isolated in Example 1-2 was dissolved in NMP and NHS (10 equivalents of Fmoc-Lysine-loaded resin), DCC (10 equivalents of Fmoc-Lysine- ) And activate it.

8. Add the solution to the YGGFLRKYPK-loaded resin with Fmoc removed.

9. After the final synthesis, wash 3 times with DCM solution, 3 times with NMP solution and 3 times with DCM solution. Dry the sample under vacuum.

10. Cleave the Protecting group with a solution of phenol, distilled water, EDT (Ethandithio), TFA (Trifluoroacetic acid), and Thioanisole.

11. Process the pre-cooled Ether and centrifuge.

12. The solid material is dissolved in the solvent and filtered, and then purified using Reverse Phase (RP) -HPLC (Waters system) with C18 column.

13. The purified material is lyophilized to a powder state.

14. Determine molecular weight with MALDI-TOF mass spectrometry (Voyager DE-STR).

Shinorine - Neoendorphin

In case of Shinorine - Neoendorphin, same as above but use Shinorine instead of Porphyra in 7).

Palythine - Neoendorphin

In the case of Palythine-Neoendorphin, it is the same as above, except that Palythine is used instead of Porphyra in 7).

Asterine - Neoendorphin

In case of Asterine-Neoendorphin, same as above but use Asterine instead of Porphyra in 7).

Porphyra  334+ shinorine + palythine + Asterine Neoendorphin

In the case of Porphyra 334 + shinorine + palythine + Asterine Neoendorphin, same as above but use Porphyra 334 + shinorine + palythine + Asterine instead of Porphyra in 7).

(2) Synthesis of Porphyra334-Exorphin (YGGWL: SEQ ID NO: 2)

1. Place the Fmoc-Leucine-loaded resin into the vessel, dissolve in NMP (N-Methylpyrrolidinone) and infuse the resin for 20 minutes.

2. A solution of piperidine (20%) and NMP (80%) was added to the inflated resin and the reaction was repeated twice for 10 minutes.

3. Wash 3 times with DCM (Dichloromethane) solution and 3 times with NMP solution.

4. Fmoc-Tryptophan amino acid (10 equivalents of Fmoc-Leucine-loaded resin) was dissolved in NMP, and NHS (N-Hydroxysuccinimide) (10 equivalents of Fmoc-Leucine-loaded resin), DCC (Dicyclohexylcarbodiimide -loaded resin 10 equivalents).

5. Add 4 solutions of Fmoc-removed Leucine-loaded resin and mix.

6. Repeat step 25 until the sequence Pentapeptide (sequence: YGGWL) is synthesized.

7. Porphyra ( 10 equivalents of Fmoc-Leucine-loaded resin) isolated in Example 1-2 was dissolved in NMP, and NHS (10 equivalents of Fmoc-Leucine-loaded resin) and DCC (10 equivalents of Fmoc- ) And activate it.

8. Add the solution to the YGGWL-loaded resin with Fmoc removed.

9. After the final synthesis, wash 3 times with DCM solution, 3 times with NMP solution and 3 times with DCM solution. Dry the sample under vacuum.

10. Cleave the Protecting group with a solution of phenol, distilled water, EDT (Ethandithio), TFA (Trifluoroacetic acid), and Thioanisole.

11. Process the pre-cooled Ether and centrifuge.

12. The solid material is dissolved in the solvent and filtered, and then purified using Reverse Phase (RP) -HPLC (Waters system) with C18 column.

13. The purified material is lyophilized to a powder state.

14. Determine molecular weight with MALDI-TOF mass spectrometry (Voyager DE-STR).

Shinorine - Exorphin

In case of Shinorine -Exorphin, same as above but use Shinorine instead of Porphyra in 7).

Palythine - Exorphin

In the case of Palithine-Exorphin, it is the same as above but uses Palythine instead of Porphyra in 7).

Asterine - Exorphin

In case of Asterine-Exorphin, same as above but use Asterine instead of Porphyra in 7).

Porphyra  334+ shinorine + palythine + Asterine Exorphin

For Porphyra 334 + shinorine + palythine + Asterine Exorphin, same as above but use Porphyra 334 + shinorine + palythine + Asterine instead of Porphyra in 7).

(3) Synthesis of Porphyra334-Enkephalin (YGGFL: SEQ ID NO: 3)

1. Place the Fmoc-Leucine-loaded resin into the vessel, dissolve in NMP (N-Methylpyrrolidinone) and infuse the resin for 20 minutes.

2. A solution of piperidine (20%) and NMP (80%) was added to the inflated resin and the reaction was repeated twice for 10 minutes.

3. Wash 3 times with DCM (Dichloromethane) solution and 3 times with NMP solution.

4. Fmoc-Phenylalanine amino acid (10 equivalents of Fmoc-Leucine-loaded resin) was dissolved in NMP and then N-Hydroxysuccinimide (10 equivalents of Fmoc-Leucine-loaded resin), DCC (Dicyclohexylcarbodiimide -loaded resin 10 equivalents).

5. Add 4 solutions of Fmoc-removed Leucine-loaded resin and mix.

6. Repeat step 25 until the sequence Pentapeptide (sequence: YGGFL) is synthesized.

7. Porphyra (10 equivalents of Fmoc-Leucine-loaded resin) is dissolved in NMP and activated by NHS (10 equivalents of Fmoc-Leucine-loaded resin) and DCC (10 equivalents of Fmoc-Leucine-loaded resin).

8. Add the solution to the YGGWL-loaded resin with Fmoc removed.

9. After the final synthesis, wash 3 times with DCM solution, 3 times with NMP solution and 3 times with DCM solution. Dry the sample under vacuum.

10. Cleave the Protecting group with a solution of phenol, distilled water, EDT (Ethandithio), TFA (Trifluoroacetic acid), and Thioanisole.

11. Process the pre-cooled Ether and centrifuge.

12. The solid material is dissolved in the solvent and filtered, and then purified using Reverse Phase (RP) -HPLC (Waters system) with C18 column.

13. The purified material is lyophilized to a powder state.

14. Determine molecular weight with MALDI-TOF mass spectrometry (Voyager DE-STR).

Shinorine - Enkephalin

In case of Shinorine-Enkephalin, same as the above method, but use Shinorine instead of Porphyra in 7).

Palythine - Enkephalin

In the case of Palythine-Enkephalin, this method is the same as above, except that Palythine is used instead of Porphyra in 7).

Asterine - Enkephalin

In the case of Asterine-Enkephalin, the same method as above, except that Asterine is used instead of Porphyra in 7).

Porphyra  334+ shinorine + palythine + Asterine Enkephalin

Porphyra 334 + shinorine + palythine + Asterine Enkephalin is the same as above, except that Porphyra 334 + shinorine + palythine + Asterine is used instead of Porphyra in 7).

Experimental Example  1: microalgae according to the present invention Chlamydomonas sp .Wow Chlamydomonas hedley  Derived from extracts and microalgae extract MAAs  - Neuropeptide of In skin cell viability (cell viability)  Impact test

The microalgae Chlamydomonas prepared in Example 1 sp ., Chlamydomonas Human keratinocyte cells (HaCaT) were cultured in an ATCC (American Type Culture Collection) in order to examine the proliferative activity of skin cells on MAAs -Neuropeptide derived from hedleyi extract and microalgae extract. Each cell was inoculated into a 24-well culture plate at a concentration of 1 × 10 ⁴ cells / ml. The medium was DMEM (Dubelco's Modified Eagle Medium, BRL, USA) containing 10% FBS. After culturing for 48 hours in DMEM containing 10% FBS and culturing for 25-30% of the surface area of the culture dish, FBS-free DMEM containing the composition prepared in Example 1 was replaced with another culture for 24 hours. 50 μl of a solution of 2.5 mg / ml of 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT, Sigma M5655, USA) (DMSO, Sigma D2650, USA) solution was added to each well and the mixture was stirred for 20 minutes to dissolve the formazan crystals. Then, 100 μl of each of the formazan crystals was dissolved in 96 wells And the absorbance at 570 nm was measured by Enzyme-Linked Immunosorbent Assay (ELISA). The degree of proliferative activity of skin cells was calculated by the following formula based on the absorbance intensity of the control group using pure water and expressed as a percentage. The results are shown in Table 2.

[Equation 1]

Cell viability effect (%) = [(absorbance of experiment group - absorbance of control group) / absorbance of control group]

Skin cell survival rate of Clamidomonas extract Cell viability (% of control) 0.5% 2 % Chlamydomonas sp. extract 103 108 Chlamydomonas hedleyi extract 105 115

The skin cell survival rate of the fusion peptide derivative of the present invention or a mixture of MAA and neuropeptide MAA type Neuropeptide Type Cell viability (% of control) 2 % Porphyra 334 Neoendorphin 123.2 Exorphin 124.5 Enkephalin 108.6 Shinorine Neoendorphin 108.0 Exorphin 114.0 Enkephalin 106.8 Palythine Neoendorphin 124.5 Exorphin 123.2 Enkephalin 98.3 Asterine Neoendorphin 105.4 Exorphin 110.8 Enkephalin 112.0 Porphyra 334
+ Shinorine
+ Palythine
+ Asterine Neoendorphin 102.6 Exorphin 105.1 Enkephalin 106.0

Effect on skin cytotoxicity As a result of the test, as shown in Tables 1 and 2, 0.5% and 2% of microalgae Chlamydomonas sp ., Chlamydomonas Neoendorphin , Exorphin and Enkephalin, which are MAAs derived from hedleyi extract and 2% microalgae extract, respectively, were not observed by Porphyra 334, Shinorine, Palythine, Asterine, Porphyra334 + Shinorine + Palythine + Asterine fusion neuropeptides. In other words, it was confirmed that the cell viability was not affected.

Experimental Example  2: microalgae according to the present invention Chlamydomonas sp .Wow Chlamydomonas hedley  Derived from extracts and microalgae extract MAAs  - Neuropeptide Effect of UV Protection on Cell Protection

Ultraviolet cross-linker CL-1000 (Ultra-Violet Products, CA), which emits ultraviolet rays at a wavelength of 302 nm, was used as a light source for UV irradiation. HaCaT cells were cultured in a 24-well plate at a concentration of 1 × 10 ⁵ cells / ml for 24 hours. Then, the medium was removed and washed with phosphate buffer solution. After addition of 500 ml of phosphate buffer, the cells were irradiated with ultraviolet light at 10 mJ / cm ² , replaced with fresh cell culture medium containing no FBS, treated with each concentration, and further cultured for 24 hours. After 5 mg / ml of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide, Sigma) was added and incubated for 3 hours in an incubator, the formazan formed was dissolved in DMSO, After transferring to a 96-well plate, absorbance was measured with an ELISA reader at 565 nm.

The cytoprotective effect of the fusion peptide derivative of the present invention or the mixture of MAA and neuropeptide, Clamidomonas extract, upon UV irradiation UV irradiation MAA type Neuropeptide Type Cell viability (% of control) 0.5% 2 % - Control group Control group 100






+

Control group Control group 50 Porphyra 334 Neoendorphin 65 70 Exorphin 69 67 Enkephalin 80 89 Shinorine Neoendorphin 55 57 Exorphin 51 53 Enkephalin 57 60 Palythine Neoendorphin 60 70 Exorphin 66 76 Enkephalin 68 78 Asterine Neoendorphin 51 54 Exorphin 52 55 Enkephalin 51 53 Porphyra 334
+ Shinorine
+ Palythine
+ Asterine Neoendorphin 60 70 Exorphin 65 75 Enkephalin 68 78 Chlamydomonas sp. 55 60 Chlamydomonas hedleyi 59 65

0.5% and 2% microalgae Chlamydomonas sp ., Chlamydomonas To investigate the effect of neoendorphin, exorphin and enkephalin, which are MAAs derived from hedleyi extract and 2% microalgae extract, on the keratinocyte cytotoxic effect on ultraviolet light by Porphyra 334, Shinorine, Palythine, Asterine, Porphyra334 + Shinorine + Palythine + Asterine fusion neuropeptides As a result, as shown in Table 3, as the concentration was increased, it showed excellent cytoprotective effect against ultraviolet irradiation as compared with the control group.

Experimental Example 3: SPF (ultraviolet barrier index) measurement by in-vivo test

SPF (ultraviolet barrier index) was measured through an in-vivo test in order to examine the degree of ultraviolet shielding in the above Examples and Comparative Examples. That is, the fusion peptide derivative of the present invention obtained in Example 1, or a mixture of MAA and neuropeptide and Clamidomonas extract was added to purified water at a concentration of 7% to prepare a standard sample. 10 or more test subjects were selected, and the skin was damaged, excessive hair and hue were avoided, and the skin was clean and dry. After that, the skin type of the subject was surveyed through a questionnaire, and the expected minimum erythema was determined based on the questionnaire and a solar simulator equipped with a Xenon arc lamp or a similar light source was examined. After the investigation, the erythema state of the test subject was judged between 1624 hours, and the minimum amount of UVB irradiated to the area where erythema was observed on the entire surface was defined as the minimum erythema amount. Then coated with a standard sample application site and the amount of product to the application site to more than 24cm ² and divided into 5 or more irradiation portion having a surface area at least 0.5cm ^2, 2.0mg / cm ² or 2.0L / cm ² to the test subjects Respectively. Thereafter, it was allowed to stand at room temperature for 15 minutes and dried. Then, the minimum erythema amount was measured in the same manner as the minimum erythema measurement before application of the product. Thereafter, the ultraviolet barrier index was calculated by the following equation (2), and the results are shown in Table 4.

&Quot; (2) "

The cytoprotective effect of the fusion peptide derivative of the present invention or the mixture of MAA and neuropeptide, Clamidomonas extract, upon UV irradiation MAA type division SPF One Control group One 2 Porphyra 334 Neoendorphin 10 3 Exorphin 10 4 Enkephalin 13 5 Shinorine Neoendorphin 15 6 Exorphin 18 7 Enkephalin 20 8 Palythine Neoendorphin 13 9 Exorphin 13 10 Enkephalin 13 11 Asterine Neoendorphin 12 12 Exorphin 14 13 Enkephalin 16 14 Porphyra 334
+ Shinorine
+ Palythine
+ Asterine Neoendorphin 20 15 Exorphin 22 16 Enkephalin 25 17 Chlamydomonas sp. 8 18 Chlamydomonas hedleyi 10

As shown in Table 4, the microalgae Chlamydomonas sp ., Chlamydomonas It was confirmed that the ultraviolet barrier index of Neoendorphin, Exorphin and Enkephalin, which are MAAs derived from hedleyi extract and microalgae extract, respectively, can be up to 25+ in the neuroendopein, exorphin and enkephalin compositions, which are Porphyra 334, Shinorine, Palythine, Asterine and Porphyra334 + Shinorine + Palythine +

Preparation of cosmetic composition

The cosmetic composition containing the fusion peptide derivative of Example 1 of the present invention or a mixture of MAA and neuropeptide and Clamidomonas extract as an active ingredient is a cosmetic product of an emulsified form such as a nutritional lotion, cream, or essence and a cosmetic product of a solubilized form .

Manufacturing example  2-1: Lotion

According to the following formulation, it was prepared according to the conventional lotion preparation method.

Raw material name Weight% (w / w) glycerin 5.0 Dipropylene glycol 3.0 Hyaluronic acid 0.5 Polyoxyethylene hardened castor oil 0.1 Polyethylene oleyl ethyl 0.1 ethanol 5.0 antiseptic 0.15 Beauty Suitable amount flash Suitable amount The fusion peptide derivative or MAA and neuropeptide mixture of Example 1, Clamidomonas extract 2.0 to 7.0 Purified water to 100

Manufacturing example  2-2: Essence

According to the following prescription, it was prepared according to a conventional method for producing essence.

Raw material name Weight% (w / w) Cetostearyl alcohol 1.0 Self emulsifying monostearic acid 1.0 Wax 0.5 Squalane 5.0 Isocetyl octanoate 3.0 Dimethylsiloxane 0.3 Sorbitan monostearate 0.5 Polyethylene glycol monostearate 8.0 glycerin 4.0 Propylene glycol 0.2 Carboxy polymer 0.22 Triethanolamine 0.25 antiseptic Suitable amount Spices Suitable amount flash Suitable amount The fusion peptide derivative or MAA and neuropeptide mixture of Example 1, Clamidomonas extract 2.0 to 7.0 Purified water to 100

Manufacturing example  2-3: Lotion

According to the following formulation, it was prepared according to a conventional lotion preparation method.

Raw material name Weight% (w / w) Cetostearyl alcohol 0.8 Self emulsifying monostearic acid 1.0 Wax 0.5 Stearic acid 0.5 Liquid paraffin 7.0 Squalane 5.0 Macadamia oil 3.0 Isocetyl octanoate 2.0 Dimethylsiloxane 0.3 Sorbitan monostearate 0.5 Polyethylene glycol monostearate 1.2 glycerin 4.0 Propylene glycol 4.0 Betaine 4.0 Carboxy polymer 0.12 Triethanolamine 0.15 antiseptic 0.25 Spices Suitable amount flash Suitable amount The fusion peptide derivative or MAA and neuropeptide mixture of Example 1, Clamidomonas extract 2.0 to 5.0 Purified water to 100

Manufacturing example  2-4: Cream

According to the following formulation, it was prepared according to a conventional cream production method.

Raw material name Weight% (w / w) Cetostearyl alcohol 3.0 Self emulsifying monostearic acid 1.5 Chin type monostearate 1.5 Wax 0.5 Liquid paraffin 8.0 Squalane 7.0 Isocetyl octanoate 4.0 Refined jojoba oil 4.0 Dimethylsiloxane 0.3 Sorbitan monostearate 1.0 Polyethylene glycol monostearate 1.2 glycerin 6.0 Propylene glycol 4.0 Betaine 4.0 Xanthan gum 0.06 Triethanolamine 0.10 antiseptic 0.25 Spices Suitable amount flash Suitable amount The fusion peptide derivative or MAA and neuropeptide mixture of Example 1, Clamidomonas extract 2.0 to 7.0 Purified water to 100

Manufacturing example  2-5: Gel

According to the following prescription, it was prepared according to a conventional gel preparation method.

Raw material name Weight% (w / w) glycerin 4.0 Propylene glycol 4.0 ethanol 10 Polyoxyethylene hardened castor oil 0.1 Carboxy polymer 0.30 Triethanolamine 0.30 antiseptic Suitable amount Spices Suitable amount flash Suitable amount The fusion peptide derivative or MAA and neuropeptide mixture of Example 1, Clamidomonas extract 1.0 to 7.0 Purified water to 100

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Unsigned

Claims (6)

Peptide derivatives in which neuropeptides are bound to mycophorine-like amino acids. The peptide derivative according to claim 1, wherein the mycophorolype-like amino acid is selected from the group consisting of Porphyra 334, Shinorine, Palythine and Asterine. The peptide derivative according to claim 1, wherein the neuropeptide is selected from the group consisting of neoendorphin, exopin, and enkephalin. 2. The peptide derivative according to claim 1, wherein the neodendrine, exopine and enkepalin are each represented by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3. 4. A UV-blocking composition comprising a peptide derivative according to any one of claims 1 to 3. A composition for protecting ultraviolet rays containing mycosole-like amino acid and neuropeptide.

Images